Cytokinetics (CYTK) Tops Q4 EPS by 43c
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $67.65 +0.13%
EPS Growth %: +43.1%
Financial Fact:
Research and development: 19.34M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: +43.1%
Financial Fact:
Research and development: 19.34M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q4 basic EPS of $0.16, $0.43 better than the analyst estimate of ($0.27), may not compare. Revenue for the quarter came in at $33.1 million versus the consensus estimate of $16.33 million.
GUIDANCE:
Cytokinetics sees FY 2017 cash revenue of $21-23 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
- Goldman: 'Our key conclusion is that AI is likely to be credit-positive for banks', 'Rearming Our Overweight Stance on Banks'
- BlockchainK2 plans private placement to raise up to $130,000
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
